Replies to post #2084 on Can Fite BioPharma Ltd (CANF)

[midastouch017]

“A first-in-class agent such as Piclidenoson that could provide neuroprotection and improve vascular health would fill a significant unmet need and likely capture a large share of the growing Vascular Dementia market.,” stated Pnina Fishman, Ph.D., Chief Scientific Officer of Can-Fite BioPharma.

[georgie18]

CANF...82...Loaded .80 this morning...🥳...S-1 in progress...

georgie18

Member Level
Re: georgie18 post# 396079

Monday, July 28, 2025 7:22:11 AM

Post#
396107
of 396150
CANF...$1.02...🥳... https://finviz.com/news/116954/breakthrough-study-from-ucla-demonstrate-can-fites-piclidenoson-as-a-treatment-for-vascular-dementia

georgie18

Member Level
Re: None

Friday, July 25, 2025 1:56:53 PM

Post#
2083
of 2084
CANF...99...🥳...https://schrts.co/PIWkzDfh ...Will add up or down...Working on S-1 being completed...

April News... https://www.globenewswire.com/news-release/2025/04/14/3060926/0/en/Can-Fite-to-Generate-685M-in-Projected-Future-Revenues-from-its-Partnerships.html